abbott

Become a Millionaire on a Minimum-Wage Salary

No, it's not easy, but if Grace Groner -- a secretary for 43 years -- could pull off the even more astonishing feat of amassing a $7 million fortune, then it is within the realm of possibility. In fact, Groner's strategy is about the only one with a shot at success. Read on to find out what she did.

DailyFinance's Top 11 Value Stocks for 2011

Wall Street expects the S&P 500 to tacking on an 11% gain over the next 12 months -- with lots of ups and downs along the way. That has us inclined to play defense in our 2011 picks, with an eye toward bargain stocks paying generous, sustainable dividends. Here are our top 11 for 2011:

What a Wild Year It Was
for Health Care

Led by the health insurance reform law, a flurry of drug and food recalls, key medical breakthroughs and plenty of layoffs and lawsuits, 2010 proved to be an exciting -- if not always positive -- year. Here's our list of the year's biggest health stories.

Merck KGaA Is Latest Pharma to Settle Justice Department Claims

German pharmaceutical and chemical company Merck KGaA will pay $280 million to settle a U.S. Department of Justice claim brought against a former subsidiary, Dey Pharma, regarding Medicare and Medicaid reimbursements. This is the fourth such settlement this month alone.

Biotechs and Big Pharma Squabble in Sweden

At a recent life-sciences conference in Stockholm, execs of several U.S. and foreign biotechs clashed with Big Pharma in a lively debate on the merits of their respective goals and products. The result, however, was a stand-off.

Abbott Pulls Weight Loss Drug Meridia from Market

Drug and medical-device maker Abbott Laboratories announced Friday that it will voluntarily withdraw its controversial obesity drug Meridia, (sibutramine) from the U.S. market at the request of the FDA, due to concerns it increases the risk of heart attacks and strokes.

Biz Brief: Abbott Licenses Potential Gynecological Drug from Neurocrine

Abbott Laboratories and Neurocrine Biosciences have entered into a collaboration agreement to develop and commercialize a potential gynecological treatment, elagolix. Elagolix, a potential oral drug, which has completed Phase IIb trials, is being developed for the treatment of endometriosis and uterine fibroids.

Abbott Becomes India's Top Drugmaker With $3.7 Billion Deal

With drug sales stalling in developed countries, Abbott Laboratories has made a bold play to harness pharma's strong growth in emerging markets. Its purchase of a Piramal Healthcare unit in India gives Abbott the largest market share in the country.

Big Pharma Eyes Developing Nations for Sales Growth

Thanks to rising affluence, more sedentary populations and Westernized diets, the demand for drugs that combat cardiovascular diseases is growing in the developing world. And Western pharmaceutical companies are paying attention.

Abbott Experiments with a $450 Million Deal for Facet

Abbott Labs announced it would acquire Facet Biotech for $27 per share. The friendly deal, which will enhance Abbott's pharmaceutical pipeline, is expected to close in the second quarter of this year and has been approved by the boards of both companies.

Bristol-Myers Squibb's Kidney Transplant Drug Gets a Nod

An FDA advisory panel recommended approval of Bristol-Myers Squibb's belatacept, an experimental drug used in kidney transplants -- with at least one caveat. It recommended further long-term studies after a full FDA approval.

Stocks in the News: Campbell Soup, Lowe's, Smith

A round-up of news that could affect stock prices today, including Cambell's Soup quarterly profit is up 11% over last year, Lowe's quarterly profit rose 27%, and Smith International agrees to Schlumberger buyout.

After Clinton's Surgery, a Primer on Stents

Bill Clinton's surgery yesterday -- inserting stents into his heart, years after his quadruple-bypass surgery -- has become a common procedure to clear plaque buildup from the surgical grafts. Here's how they work.